What is the appropriate management for a patient with constant hip pain who has had X‑rays and is receiving intramuscular methylprednisolone (Solumedrol) and ketorolac (Toradol) with a referral to physical therapy?

Management of Constant Hip Pain

The current management approach is problematic: intramuscular methylprednisolone is not the appropriate route for hip pain, and you should transition to image-guided intra-articular corticosteroid injection or consider ketorolac as a safer alternative with comparable efficacy. 1

Critical Issue with Current Treatment

The patient received IM Solu-Medrol, which is not indicated for hip osteoarthritis or musculoskeletal hip pain. The FDA labeling for Solu-Medrol specifies that intravenous injection is the preferred method for initial emergency use, with IM injection reserved for specific systemic conditions—not localized joint pain 2. This represents a fundamental misapplication of the medication.

Correct Corticosteroid Approach for Hip Pain

If proceeding with corticosteroid therapy:

• Intra-articular injection is the evidence-based route for hip osteoarthritis and persistent hip pain 1
• Image guidance (ultrasound or fluoroscopy) is mandatory for hip injections due to joint depth and proximity to neurovascular structures 1
• Methylprednisolone or triamcinolone can provide pain relief for 4-24 weeks, though effects are time-limited 1
• Avoid corticosteroid injection within 3 months of planned joint replacement surgery due to infection risk 1

Important Caveats

• Repeat intra-articular corticosteroids carry long-term risks including negative effects on bone health, joint structure, and meniscal thickness 1
• Systemic IM corticosteroids expose patients to HPA axis suppression, hyperglycemia, immunosuppression, and cardiovascular risks without targeting the affected joint 2

Ketorolac as a Preferred Alternative

Recent high-quality evidence suggests ketorolac injections may be superior to corticosteroids for hip pain:

• A 2026 study demonstrated that ultrasound-guided ketorolac (30 mg) provided significantly greater pain reduction than corticosteroids for hip OA, femoroacetabular impingement, and extra-articular tendinopathy 3
• Duration of effect was comparable (93 days for ketorolac vs 128 days for steroids, not statistically different) 3
• Ketorolac avoids the catastrophic risks associated with corticosteroids (joint degradation, infection, metabolic effects) while providing similar or better symptom relief 4
• This approach is supported by a 2026 editorial arguing that when efficacy is similar, the agent with fewer serious risks should be preferred 4

Ketorolac Injection Protocol

• 30 mg ketorolac via ultrasound-guided intra-articular injection
• Image guidance remains essential for hip injections regardless of injectate 3
• Onset of effect typically within 3-4 days 3

Comprehensive Management Algorithm

1. First-line foundation (should already be initiated):

• Physical therapy referral (already done—appropriate) 1
• Self-management program education 1
• Topical NSAIDs if knee involvement (not effective for hip due to depth) 1

2. Oral pharmacotherapy options:

• Oral NSAIDs (first-line for hip OA pain) 5, 1
  • Screen for cardiovascular disease, chronic kidney disease, and GI bleeding risk
  • Avoid if eGFR <30 mL/min/1.73m² 1
  • Add PPI or misoprostol if GI risk factors present 1
• Acetaminophen (conditional recommendation, modest efficacy)
  • Maximum 3-4 grams daily, monitor hepatotoxicity 5, 1
• Duloxetine 30-60 mg daily (alternative or adjunct to NSAIDs) 5, 1
  • Particularly useful if central pain sensitization suspected
  • Must be taken daily, not as needed
  • Taper over 2-4 weeks if discontinuing 1

3. Injectable therapy (if oral medications insufficient):

• Option A: Ultrasound-guided intra-articular ketorolac 30 mg (preferred based on 2026 evidence) 3, 4
• Option B: Ultrasound-guided intra-articular corticosteroid (methylprednisolone or triamcinolone) 1

4. What to avoid:

• IM corticosteroids for hip pain (current approach—discontinue) 2
• Tramadol and opioids (recommended against due to limited benefit and high adverse event risk) 5, 1
• Systemic ketorolac (the current IM Toradol may provide temporary systemic analgesia but doesn't address the joint pathology and carries GI/renal risks with prolonged use)

Diagnostic Considerations

Since X-rays have been completed, assess for:

• Osteoarthritis (joint space narrowing, osteophytes, subchondral sclerosis)
• Femoroacetabular impingement syndrome (younger patients, activity-related pain)
• Extra-articular pathology (trochanteric bursitis, gluteal tendinopathy, iliopsoas tendinopathy)

Do not obtain MRI for diagnosis of hip OA—this is strongly recommended against by VA/DoD guidelines 1. MRI is reserved for suspected soft tissue pathology, labral tears, or when diagnosis remains unclear after X-ray and clinical examination.

Immediate Action Steps

1. Discontinue IM Solu-Medrol—this is not indicated for hip pain
2. Continue physical therapy as already initiated
3. Initiate oral NSAID (if no contraindications) or duloxetine
4. Arrange ultrasound-guided intra-articular injection with ketorolac 30 mg as first choice, or corticosteroid if ketorolac unavailable
5. Reassess in 4-6 weeks for response and need for additional interventions

The combination of PT, appropriate oral pharmacotherapy, and properly administered intra-articular injection (preferably ketorolac) represents the evidence-based standard for persistent hip pain management 1, 3.